IMPAACT 2008 is a phase I/II, multisite, randomized open-label study which evaluates the safety and antiviral activity on HIV-1 DNA levels of VRC01 in infants living with HIV-1 beginning combination antiretroviral therapy (cART). Dr Alka Khaitan (Indiana University School of Medicine, Indianapolis, IN, USA) joins touchINFECTIOUS DISEASES to discuss the efficacy ans safety findings of the IMPAACT 2008 study.
The presentation entitled ‘Phase I/II study of monoclonal antibody VRC01 with early antiretroviral therapy to promote clearance of HIV-1 infected cells in infants (IMPAACT 2008)’ was presented at the International AIDS Society (IAS) 29 July – 2 August, 2022.
- What is VRC01 and what evidence supports its use in infants? (00:17)
- What were the aims, design and study population of the IMPAACT 2008 clinical trial? (02:02)
- What were the efficacy and safety findings of the study? (03:57)
- What will be the next steps in the clinical development of VRC01 in this indication? (05:42)
Disclosures: Alka Khaitan has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen.
Share this Video
Related Videos In HIV
Updated HIV primary care guidelines: Mamta Jain, ACTHIV 2023
Updated HIV primary care guidelines provide evidence-based and standardized approaches to manage individuals living with HIV, addressing their unique needs and challenges. By following these guidelines, healthcare providers can enhance patient outcomes and stay abreast of the latest research and treatment advancements in HIV care. In this interview, we speak with Dr Mamta Jain (UT […]
Managing liver complications and drug-drug interactions in HBV-HIV co-infection: ACTHIV 2023 with Jessie Torgersen
Liver complications and drug-drug interactions in HBV viremia in HIV patients are common, so it is important to consider complications and follow appropriate guidelines for patients when prescribing treatment. In this interview, we speak with Dr Jessie Torgersen (University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA) to explore considerations for healthcare professionals, including liver complications […]
HIV-HBV co-infection screening and monitoring guidelines: ACTHIV 2023, Jessie Torgersen
Screening and managing HIV-hepatitis B virus (HBV) co-infection is important due to increased risks in patients, therefore it is important to ensure standard practices involve comprehensive assessment, including serological testing and liver function evaluation, and healthcare professionals follow guidelines for regular monitoring to assess disease progression and treatment response. In this interview, we speak with […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!